Questions About Cancer? 1-800-4-CANCER

Featured Clinical Trials

Highlighted NCI-Supported Cancer Studies

Esophageal Cancer - Featured Clinical Trials

The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:

Genetically Engineered Immunotherapy for Advanced Cancer
(Posted: 08/07/2012) - In this trial, doctors will collect T lymphocytes from the blood of patients with advanced mesothelin-expressing cancer and genetically engineer these cells to recognize mesothelin. The gene-engineered cells will then be multiplied and infused into the patients to fight their cancer.

Adding Targeted Therapy to Treatment for Esophageal Cancer
(Posted: 06/28/2011) - In this phase III clinical trial, people with confirmed HER2-positive locally advanced esophageal cancer will be randomly assigned to receive preoperative radiation therapy and chemotherapy, with or without trastuzumab. Following surgery, patients assigned to the trastuzumab arm of the study will receive maintenance therapy with trastuzumab for 1 year.

Targeting the Hedgehog Pathway in Stomach Cancer
(Posted: 06/01/2010) - This phase II will recruit patients with inoperable cancer of the stomach or gastroesophageal junction who have not been previously treated for advanced disease. They will be randomly assigned to receive either the combination chemotherapy regimen FOLFOX plus the Hedgehog antagonist GDC-0449 or FOLFOX plus a placebo.

Cetuximab and Chemoradiotherapy for Locally Advanced Esophageal Cancer
(Posted: 05/19/2009) - In this trial, patients with locally advanced esophageal cancer will undergo chemoradiotherapy using the drugs cisplatin and paclitaxel, and half of them will be randomly assigned to also receive the biologic agent cetuximab.

Combining Targeted Therapies for Thoracic Cancers
(Posted: 09/26/2006) - In this trial, patients with advanced thoracic cancers (cancers of the chest) or other cancers that have spread to the chest will be treated with the drugs romidepsin and flavopiridol. Researchers will study the safety of this combination and how these agents affect gene and protein expression in these patients.